文献速递糖尿病

以NAVIGATOR数据为基础的模拟研究:延迟糖尿病发病干预措施的成本效果基准分析

Benchmarking the Cost-Effectiveness of Interventions Delaying Diabetes: A Simulation Study Based on NAVIGATOR Data.
PubMed 文献 · Diabetes Care · 2020-08-12

基于NAVIGATOR研究中3058例发展为2型糖尿病的受试者,使用UKPDS-OM2模型模拟延迟糖尿病发病1-9年对成本和QALY的影响。延迟9年时美国场景QALY增益0.15,并发症费用节省8437美元;按每QALY 10万美元和2万英镑阈值,年干预成本分别不超过567-2680美元和201-947英镑即具成本效果。

要点

  • 延迟糖尿病发病1-9年,QALY增益从0.02增至0.15(美国场景)。
  • 并发症费用节省从延迟1年的1388美元增至延迟9年的8437美元。
  • 按每QALY 10万美元阈值,美国年干预成本567-2680美元内具成本效果。

核心结论

  • 模拟假设性延迟糖尿病干预可指导达到成本效果所需的最大干预成本和最短延迟时间。
  • 结果可为糖尿病预防策略的讨论和未来干预研究的设计提供参考。

研究设计与样本

  • 基于NAVIGATOR研究中9306例受试者里3058例发展为2型糖尿病者的数据,使用英国前瞻性糖尿病研究结局模型第2版(UKPDS-OM2)进行模拟。
  • 模拟延迟糖尿病发病1-9年的影响,成本和效用权重来自美国和英国场景,成本以2017年币值表示,估算贴现终生成本和QALY并给出95%CI。

主要发现

  • QALY增益从延迟1年的0.02(美国场景,95%CI 0.01, 0.03)增至延迟9年的0.15(美国场景,95%CI 0.10, 0.21)。
  • 并发症费用节省从延迟1年的1388美元(95%CI 1092, 1669)增至延迟9年的8437美元(95%CI 6611, 10197)。
  • 随着模拟延迟从1年增至9年,年干预成本在美国每QALY 10万美元阈值下不超过567-2680美元、在英国每QALY 2万英镑阈值下不超过201-947英镑即具成本效果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate using the UK Prospective Diabetes Study Outcomes Model Version 2 (UKPDS-OM2) the impact of delaying type 2 diabetes onset on costs and quality-adjusted life expectancy using trial participants who developed diabetes in the NAVIGATOR (Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research) study. RESEARCH DESIGN AND METHODS: We simulated the impact of delaying diabetes onset by 1-9 years, utilizing data from the 3,058 of 9,306 NAVIGATOR trial participants who developed type 2 diabetes. Costs and utility weights associated with diabetes and diabetes-related complications were obtained for the U.S. and U.K. settings, with costs expressed in 2017 values. We estimated discounted lifetime costs and quality-adjusted life years (QALYs) with 95% CIs. RESULTS: Gains in QALYs increased from 0.02 (U.S. setting, 95% CI 0.01, 0.03) to 0.15 (U.S. setting, 95% CI 0.10, 0.21) as the imposed time to diabetes onset was increased from 1 to 9 years, respectively. Savings in complication costs increased from $1,388 (95% CI $1,092, $1,669) for a 1-year delay to $8,437 (95% CI $6,611, $10,197) for a delay of 9 years. Interventions costing up to $567-$2,680 and £201-£947 per year would be cost-effective at $100,000 per QALY and £20,000 per QALY thresholds in the U.S. and U.K., respectively, as the modeled delay in diabetes onset was increased from 1 to 9 years. CONCLUSIONS: Simulating a hypothetical diabetes-delaying intervention provides guidance concerning the maximum cost and minimum delay in diabetes onset needed to be cost-effective. These results can inform the ongoing debate about diabetes prevention strategies and the design of future intervention studies.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Leal J, Reed SD, Patel R, et al. Benchmarking the Cost-Effectiveness of Interventions Delaying Diabetes: A Simulation Study Based on NAVIGATOR Data. Diabetes Care. 2020. PMID: 32796009. doi:10.2337/dc20-0717

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。